Key result
High sST2 after primary PCI predicts ~268% higher 30-day MACE risk in STEMI patients.
Why the study?
The study investigated the level of soluble suppression of tumorigenicity-2 (sST2) in patients with acute STEMI following primary PCI to evaluate it as a biomarker for clinical management and prognosis assessment.
Does a high sST2 level predict increased risk of 30-day MACEs in STEMI patients following primary PCI?
Observational (n=148)
No
Does a high sST2 level predict increased risk of 30-day MACEs in STEMI patients following primary PCI?
Effect estimate: OR 3.680 (95% CI 1.283-10.556)
Absolute Event Rate: 28.8% vs 8%
p-value: p=0.015
sST2 level after primary PCI is an independent predictor of 30-day MACEs in STEMI patients, suggesting its utility as a short-term prognostic biomarker.
May support short-term risk stratification post-PCI; hypothesis-generating for sST2 in STEMI, needing prospective validation.
AIM: The objective of this study was to investigate the level of soluble suppression of tumorigenicity-2 (sST2) in patients with acute ST-segment elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI), and to provide a new biomarker for clinical management and prognosis assessment. METHOD: This was a prospective study. 148 STEMI patients following primary PCI were enrolled and divided into 2 groups by the median value of sST2 and afterwards followed up for 30 days to access the occurrence of major adverse cardiac events (MACEs), which were defined as cardiovascular death, heart failure and recurrent MI. RESULTS: sST2 ranged from 20.57 to 98.96 ng/mL. High sST2 group had higher MACEs rate compared to low sST2 group (28.8% vs. 8.0%, P = 0.001). sST2 was positively correlated with age (r = 0.181, P = 0.027), SYNTAX score (r = 0.257, P = 0.002), high-sensitive C-reactive protein (hs-CRP) (r = 0.225, P = 0.006), B-type natriuretic peptide (BNP) (r = 0.225, P = 0.006) and negatively with left ventricle ejection fraction (LVEF) (r = -0.197, P = 0.016). After adjustment for clinical variables, sST2 level (OR 3.680, P = 0.015) and LVEF (OR 0.880, P < 0.001) remained independent predictors of 30-days MACEs. In receiver operating characteristic curve (ROC) analyses, the area under the curve (AUC) of sST2 for predicting 30-days MACEs was 0.755(P < 0.001). The AUC of sST2 combining hs-CRP and LVEF for prediction was 0.828(95%CI [0.743-0.912], P < 0.001). CONCLUSION: sST2 level after primary PCI was an independent risk factor of MACEs in STEMI patients through 30 days follow-up.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) conducted an observational in Acute ST-segment elevation myocardial infarction (STEMI) (n=148). High sST2 (> 37.49 ng/mL) vs. Low sST2 (≤ 37.49 ng/mL) was evaluated on 30-day Major adverse cardiac events (MACEs) (OR 3.680, 95% CI 1.283-10.556, p=0.015). High sST2 levels (>37.49 ng/mL) after primary PCI independently predicted a higher 30-day risk of major adverse cardiac events compared to low sST2 levels in STEMI patients (OR 3.680).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: